B Braun buys McGaw for $320 million:
This article was originally published in Clinica
Executive Summary
German company B Braun Melsungen has bought Ivax subsidiary McGaw, which makes intravenous solutions and related products, for around $320 million. B Braun will make additional payments of up to $80 million, depending on the operating results of McGaw and B Braun's US subsidiary. US company Ivax will receive royalties based on B Braun and McGaw's commercialisation of Duplex, a multi-compartment drug-delivery system designed for intravenous drugs that have limited stability after mixing.
You may also be interested in...
Building On Successes During Turbulent Times, SR One Closes $600m Fund II
SR One will keep investing in a mix of new companies, early-stage firms and later opportunities with its second fund, raised even as biotech continues to endure challenging financial times.
Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.
Generic Pylera Leads Charge As Endo Aims To Fix Up Floundering Business
Endo has launched the first generic version of Allergan’s H. pylori treatment Pylera and plans to launch around 10 products from its sterile injectables and generics businesses this year.